Ernexa Therapeutics Inc. Deferred Tax Assets, Net of Valuation Allowance
Ernexa Therapeutics Inc. (ERNA) had Deferred Tax Assets, Net of Valuation Allowance of $259.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2026-03-13
- 2025-12-31: Deferred Tax Assets, Net of Valuation Allowance $259.00K.
- 2024-12-31: Deferred Tax Assets, Net of Valuation Allowance $324.00K.
- 2023-12-31: Deferred Tax Assets, Net of Valuation Allowance $10.98M.
- 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $396.00K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance | Deferred Tax Assets, Net of Valuation Allowance as first filed |
|---|---|---|
| 2025-12-31 | $259.00K 10-K · filed 2026-03-13 | |
| 2024-12-31 | $324.00K 10-K · filed 2026-03-13 | |
| 2023-12-31 | $10.98M 10-K · filed 2025-03-12 | |
| 2022-12-31 | $396.00K 10-K · filed 2024-03-14 | |
| 2021-12-31 | $921.00K 10-K · filed 2023-03-20 | $280.00K 10-K · filed 2022-04-15 |
| 2020-12-31 | $0.00 10-K/A · filed 2022-07-01 | $449.00K 10-K · filed 2021-03-11 |
| 2019-12-31 | $1.15M 10-K · filed 2021-03-11 | |
| 2018-12-31 | $677.00K 10-K · filed 2020-03-19 | |
| 2017-12-31 | $592.00K 10-K · filed 2019-03-22 | $372.00K 10-K · filed 2018-03-09 |
| 2016-12-31 | $441.00K 10-K · filed 2018-03-09 | |
| 2015-12-31 | $415.00K 10-K · filed 2017-03-09 | |
| 2014-12-31 | $699.00K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |